The in vitro activity of the aminoglycoside antibiotic tobramycin was demonstrated by broth dilution and single-disc methods on 50 isolates each of Staphylococcus aureus, Klebsiella or Enterobacter, indole-positive and -negative Proteus, Escherichia coli, and Pseudomonas aeruginosa. All organisms were inhibited by 6.25 Mug or less of the drug/ml. Pseudomonas strains resistant to kanamycin or gentamicin or both were susceptible to tobramycin. Those strains which were inhibited by 6.25 MAg of tobramycin/ml by the broth dilution method had zone diameters of 16 mm or more by the single-disc method. Of 313 organisms tested by the disc method, 3 strains were found to be resistant to tobramycin, 73 were resistant to kanamycin, and 18 were resistant to gentamicin. Tobramycin was found to have satisfactory in vitro activity against many clinically important organisms, including strains resistant to gentamicin and kanamycin.
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Nebramycin is an antibiotic compound derived from the soil saprophyte Streptomyces tenebrarius. This compound is an aminoglycoside similar in structure to kanamycin, gentamicin, and neomycin and can be separated into eight active factors. After preliminary testing of each, factor 6, tobramycin, was found to have the highest specific activity and broadest spectrum.
This study was undertaken to determine the susceptibility of clinically important species of gram-negative bacilli and Staphylococcus aureus to tobramycin in vitro, using both broth dilution and single-disc techniques.
MATERIALS AND METHODS Organisms. The strains tested (from the Clinical Bacteriology Laboratory, Grady Memorial Hospital, Atlanta, Ga.) were obtained from specimens of pus, urine, and blood. Included were 50 strains each of Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Klebsiella or Enterobacter, indole-positive Proteus, and indole-negative Proteus, a total of 300.
Thirteen gentamicin-resistant strains of P. aeruginosa (provided by J. A. Shulman) were also studied. These were isolated from burned patients. was added to serial twofold dilutions of the drug being tested in Mueller-Hinton broth (BBL). For each organism, a growth control was included. The total volume in each tube was 1 ml, and the final concentrations of drug ranged from 50 ug/ml to 0.1 ,Ag/ml. The results were read after 18 hr of incubation at 37 C. The minimal inhibitory concentration (MIC) was the lowest concentration of drug in which there was no visible turbidity.
Disc susceptibility tests. Disc susceptibility tests were done as described by Bauer et al. (1) with the modifications proposed in the Federal Register (3).
RESULTS
Susceptibility to tobramycin. All fifty of the coagulase-positive strains of staphylococci tested were susceptible to 0.39 ,Ag or less of the drug/ml, the mode of the MIC values being .0.1 Ag/ml (Table 1 ). The MIC values of the 50 indole-positive Proteus strains tested ranged from 0.39 to 3.12 ,ug/ml with a mode of 0.78 ,ug/ml, whereas the indole-negative Proteus strains were susceptible to 0.78 to 3.12 MAg/ml, the mode being 1.56 ,ug/ml. For the strains of E. coli tested, the range of MIC values of tobramycin was 0.39 to 6.25 ,ug/ml; the mode was 0.78. Eight Enterobacter and 42 Klebsiella strains were studied; these will be described as a group since all were equally susceptible to the antibiotics tested. The modal MIC of tobramycin for these organisms was 0.2 ,ug/ml; the range was < 0.1 to 1.56 ,ug/ml. Correlation of disc and broth dilution methods with tobramycin. Figure 1 shows the zone sizes were less than 18 mm. Ten of these were in the intermediate range and showed zones between 14 and 18 mm (two indole-positive and five indole-negative strains of Proteus, two strains of Klebsiella, and one strain of Pseudomonas). The remaining kanamycin-resistant strains showed zone diameters of less than 14 mm (usually no zone) and included 60 strains of P. aeruginosa, and one each of indole-positive Proteus, E. coli, and Enterobacter. Eighteen of the strains showed zone sizes of less than 13 mm when tested with gentamicin (10 ,ug) discs. Of these, five were part of the unselected group of P. aeruginosa obtained from the hospital laboratory, and the remaining 13 were strains ofP. aeruginosa isolated from burn patients and selected for study because of their known resistance to gentamicin.
DISCUSSION
In this study, tobramycin was found to be an effective inhibitor of growth of a wide variety of organisms. Of 300 freshly isolated strains of S. aureus, Proteus, E. coli, Klebsiella or Enterobacter, and P. aeruginosa, all but four had an MIC of tobramycin of 3.12 mg/ml or less and a zone diameter of 16 mm or more (Fig. 1 ). All strains of S. aureus were inhibited by 0.39 ,ug of tobramycin/ml; Proteus strains were inhibited by 3.12 Ag/ml; all but two E. coli strains were inhibited by less than 6.25 jig/ml; all Klebsiella and Enterobacter strains were inhibited by less than 3.12 ,ug/ml; and all Pseudomonas strains were inhibited by less than 6.25 Ag/ml (Table 1) . These results are only slightly different than those of Black and Griffith (2) In one strain of P. aeruginosa, the two methods of testing did not show correlation. In this case, a zone diameter of 14 mm and an MIC of 0.2 Mg tobramycin/ml (clearly indicating susceptibility) were found. A similar finding has been previously reported by Traub in 18.6 % ofPseudomonas tested with gentamicin (7).
Preliminary multiple-dose studies in human volunteers with tobramycin showed that blood levels above those required to inhibit the organisms we tested in vitro are obtained with reasonable intramuscular doses without evidence of otic or renal toxicity (Clinical Investigaiion Manual; personal communication, R. S. Griffith, Eli Lilly and Company).
Thus, judging from preliminary clinical data and in light of the in vitro data presented here, it appears that tobramycin is a promising aminoglycoside antibiotic for use against clinically important bacteria, including gentamicin-resistant Pseudomonas.
